| 0.8 -0.1 (-11.15%) | 04-24 13:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.16 | 1-year : | 1.36 |
| Resists | First : | 1 | Second : | 1.16 |
| Pivot price | 0.84 |
|||
| Supports | First : | 0.69 |
Second : | 0.51 |
| MAs | MA(5) : | 0.86 | MA(20) : | 0.84  |
| MA(100) : | 0.8 |
MA(250) : | 1.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 58.6 |
D(3) : | 53.8 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 6.9 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CWBR ] has closed above bottom band by 32.6%. Bollinger Bands are 0.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.81 | 0.81 - 0.81 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.79 - 0.8 | 0.8 - 0.81 |
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Thu, 25 Apr 2024
CohBar to Present at the H.C. Wainwright Global Life Sciences Conference - The Globe and Mail
Tue, 19 Sep 2023
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger ... - Business Wire
Tue, 23 May 2023
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage ... - Yahoo Finance
Tue, 23 May 2023
Why Is CohBar (CWBR) Stock Up 130% Today? - InvestorPlace
Tue, 23 May 2023
CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates - Yahoo Finance
Wed, 25 Jan 2023
Is CohBar Inc (CWBR) Stock a Good Value Wednesday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 6.2 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 29 (K) |
| EPS | -4.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.4 % |
| Return on Equity (ttm) | -84 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|